| HOME >> BIOLOGY >> TECHNOLOGY |
"The publication of the new 2008 ACCP guidelines suggesting the use of pharmacomechanical thrombolysis clearly establishes a new standard for thrombolytic therapy. We believe the Trellis(R) Isolated Pharmacomechanical Thrombolysis method provides the best available combination of safety and efficacy," remarked Scott Cramer, President and CEO of Bacchus Vascular, Inc.
Isolated pharmacomechanical thrombolysis using the Trellis Peripheral Infusion System from Bacchus Vascular, Inc. to deliver thrombolytic directly into a desired treatment segment has proven to be a rapid, effective and safe method of treating patients with acute DVT. The Trellis device is the only DVT treatment system that isolates the thrombus and targets the thrombolytic treatment.
About Bacchus Vascular
Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.
For more information, visit http://www.bacchusvascular.com.
For complete information on the new ACCP VTE Guidelines, visit: http://www.TheNewGuidelines.org.
| SOURCE Bacchus Vascular, Inc. Copyright©2008 PR Newswire. All rights reserved |